An Oncology biotech pioneering RAD51 inhibition and other DDR mechanisms
Dr. John Bondo Hansen is a seasoned Medicinal Chemist and formally Vice President of Medicinal Chemistry at Novo Nordisk. Dr. Hansen worked in drug discovery in positions of increasing responsibility. He was the co-founder and member of management of several companies including Contera Pharma, which was acquired by Bukwang Pharma of Korea in 2014.
Dr. John Bondo Hansen joins Satya’s Advisory Board Read More »
Satya announced presentation of poster on Preclinical data for its SOS1 inhibitor program SAT101 at the AACR 2021. Poster Title: Identification of novel SOS1-K-Ras disruptors for NSCLC and colon cancers with K-Ras mutation. Poster Title: Identification of novel SOS1-K-Ras disruptors for NSCLC and colon cancers with K-Ras mutation. Poster number: LB117 April 10, 2021 Saturday
Satya has inaugurated its new R&D facilities in Hyderabad, comprising Medicinal Chemistry, Biochemistry, Cell and assay biology labs on March 15, 2021. Satya @ JPM Satya is at JPM 2013 in SFO (Jan 9-12, 2023). Please contact murthycsn@satyarx.com, to set up a meeting
Satya Inaugurates New R&D facility in Hyderabad Read More »
